Two months removed from winning European approval for its lead drug, Italian biotech Newron Pharmaceuticals has raised $25.5 million to jump-start its pipeline assets, pushing forward with a stable of CNS candidates.
Source: Resurgent Newron hauls in $25.5M for its CNS pipeline